Introduction
Aplastic anemia (AA) is defined as peripheral blood pancytopenia caused by bone marrow failure, and the pathogenesis is thought to involve autoimmune processes. [1] [2] [3] Several studies have confirmed immunosuppressive therapy (IST) with antithymocyte globulin (ATG) and cyclosporine (CyA) as a promising therapeutic option for patients lacking HLA-identical related donors. [4] [5] [6] [7] [8] Although several potential markers of IST response that appear to reflect the immune pathophysiology of AA have been suggested, mainly from adult studies, [9] [10] [11] none have been widely accepted. We have already investigated the clinical relevance of HLA, a minor population of paroxysmal nocturnal hemoglobinuria-type cells, and a specific autoantibody associated with AA in pediatric patients, finding no correlation between these markers and response to therapy. 12 Some groups have recently shown that pretreatment laboratory variables are associated with good response to IST, but those results remain controversial, as the numbers of children included in the study was relatively small and the drugs used for IST have not been consistent. [13] [14] [15] The present study therefore evaluated whether clinical and laboratory findings before treatment could predict IST response in a large population of children with AA enrolled in a multi-center study.
Design and Methods

Patients
Between October 1997 and September 2006, a total of 312 Japanese children with AA from 118 hospitals were enrolled in the AA-97 multicenter study conducted by the Japan Childhood Aplastic Anemia Study Group. Patients with acquired AA were eligible if the following criteria were met: age <18 years; newly diagnosed disease (≤180 days) without specific prior treatment; and moderate to very severe AA. The disease was considered severe if at least 2 of the following were noted: neutrophil count <0.5×10 9 /L; platelet count <20×10 9 /L; or reticulocyte count <20×10 9 /L with hypocellular bone marrow. 16 AA was considered very severe if the criteria for severe disease were fulfilled and neutrophil count was <0.2 ×10 9 /L. Moderate disease was defined by at least 2 of the following: neutrophil count <1.0×10 9 /L; platelet count <50×10 9 /L; or reticulocyte count <60×10 9 /L. 6 Patients with congenital AA or paroxysmal nocturnal hemoglobinuria were excluded. Allogeneic stem cell transplantation was recommended for patients with severe or very severe disease who had an HLA-matched sibling, so these patients were not included in the AA-97 study. Written informed consent was obtained from all parents and all patients >10 years old. All study protocols were approved by the ethics committee of each participating hospital. The study also conforms to the recently revised Declaration of Helsinki.
IST
All patients were treated with a combination of intravenous ATG (Lymphoglobulin;
Genzyme, Cambridge, USA) at 15 mg/kg/day for 5 days and oral CyA at 6 mg/kg/day. The dose of
CyA was adjusted to maintain trough levels between 100 and 200 ng/mL, and the appropriate dose was administered for at least 6 months. Granulocyte colony-stimulating factor (Filgrastim; Kirin, Tokyo, Japan) was administered intravenously or subcutaneously at 400 µg/m 2 for 3 months to only patients with very severe disease. 17 Response to IST was evaluated at 6 months after initiation of therapy. Complete response (CR) was defined as a neutrophil count >1.5 ×10 9 /L, a platelet count >100×10 9 /L, and a hemoglobin level >11.0 g/dL. 17 Partial response (PR) was defined as a neutrophil count >0.5 ×10 9 /L, a platelet count >20×10 9 /L, and a hemoglobin level >8.0 g/dL in patients with severe or very severe AA, and as a neutrophil count >1.0 ×10 9 /L, a platelet count >30 ×10 9 /L, and a hemoglobin level >8.0 g/dL in patients with moderate AA. 17 Overall response was defined as CR or PR at 6 months after IST.
Statistical analyses
Parameters for univariate analyses to determine predictors of response to IST included age at diagnosis, sex, interval between diagnosis and treatment, etiology, severity of disease, white blood cell (WBC) count, neutrophil count, lymphocyte count, hemoglobin level, reticulocyte count, and platelet count. Pretreatment laboratory values were defined as the lowest value without transfusions during the 4 weeks preceding IST. Continuous variables were divided into quartile categories, and these cutoffs were used for categorical analysis. To evaluate correlations between these parameters and response, differences in continuous variables were analyzed using the Mann-Whitney U-test and differences in frequencies were tested using the chi-squared test or Fisher's exact test. For multivariate analyses, logistic regression modeling was performed. Important covariates in the multivariate models were chosen using stepwise variable selection procedures. Values of P<0.05
were considered statistically significant.
Results and Discussion
Patient characteristics are shown in Table 1 . A total of 312 patients fulfilled the eligibility criteria. Median age at diagnosis was 8 years. Severity of AA was considered very severe in 156 patients, severe in 107 patients, and moderate in 49 patients. The median interval between diagnosis and treatment was 15 days. A total of 176 of the 312 (56.4%) patients improved with IST and achieved PR (n=131) or CR (n=45) at 6 months. All of them achieved transfusion independence.
To determine predictors of IST response, we compared differences in potential pretreatment variables between IST responders and non-responders. Age at diagnosis, interval between diagnosis and treatment, WBC count, neutrophil count, lymphocyte count, hemoglobin level, reticulocyte count, and platelet count were analyzed both the prevalence in categorical variables and the differences in continuous variables. In univariate analyses, WBC count, lymphocyte count, interval between diagnosis and therapy, and gender showed associations with IST response (Table 2) . We also performed multivariate logistic regression analysis to assess the simultaneous contributions of each of the variables in predicting response. In these analyses, lower WBC count (P=0.0003), shorter interval between diagnosis and therapy (P=0.012), and male sex (P=0.036) represented significant predictors of better response (Table 2) .
Boys displayed better response than girls ( Figure 1A) . This relationship was also observed in a Figure   1B ). When lymphocyte count was applied to the analysis instead of WBC count, a correlation between lower lymphocyte count and response to IST was also observed ( [20] [21] [22] More recently, oligoclonal T-cell expansions have been described in AA patients, disappearing with clinical improvement following IST. 23 Taking our results and previous findings together, a higher WBC count before treatment may indicate the presence of numerous autoreactive T cells that need to be eliminated and thus a high potential to destroy marrow function through lymphocytes, rather than better residual marrow function. In this scenario, patients with a lower WBC count could be seen to have a better probability of hematopoietic recovery following IST.
We identified a significantly inverse correlation between response and interval between diagnosis and treatment; median intervals among responders and non-responders were 13 and 19 days, respectively (P=0.002). In categorical analysis, response rates of patients with intervals <30
and ≥ 30 days were 60% and 43%, respectively (P=0.013). Figure 1C clearly indicates the inverse relationship. Notably, response rates to IST were considerably low among AA patients with long-standing disease; only 35% of patients treated ≥90 days after diagnosis responded, suggesting that patients with this condition may receive irreversible damage to hematopoietic progenitor cells or stromal elements that progresses over time, possibly due to immune attack through autoreactivated lymphocytes. The present study indicates the importance of prompt IST therapy for patients with AA.
We therefore recommend offering IST as soon as possible in all children with AA who lack a matched sibling donor.
Other variables did not differ significantly between responders and non-responders (Table 2) .
Particularly with regard to reticulocyte count, 122 patients showed reticulocyte count >25 ×10 9 /L, of whom 67 (55%) responded to IST, and 186 patients had reticulocyte count ≤25×10 9 /L, of whom 107 (58%) responded to IST. Correlations of higher reticulocyte count and higher lymphocyte count at initial diagnosis with better response to IST in patients of all ages have recently been described by the National Institutes of Health (NIH) group. 15 However, when the same analysis was applied to their 77 pediatric patients, lymphocyte count was not predictive. 14 More recently, another relatively small study in adults with AA found no such association. 13 These studies were limited by inconsistency of regimens used for IST. The current study investigated a large cohort of children with AA treated using a unified regimen, but failed to confirm any correlation between reticulocyte count and response to IST, suggesting a limited contribution of this clinical parameter to the prediction of hematopoietic recovery, at least in children.
In conclusion, pretreatment clinical and laboratory findings influence response to IST.
Favorable response correlates better with lower WBC count than with neutrophil count or disease severity, and this blood count parameter might help in clinically assessing bone marrow function.
Unlike the situation in adult AA, reticulocyte count is not predictive of response to IST in pediatric patients. IST should be started as soon as possible after diagnosis of AA, given that the response rate worsens with increasing interval between diagnosis and treatment.
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